These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 21628961)

  • 21. Histological examination on Achilles tendon lesions induced by quinolone antibacterial agents in juvenile rats.
    Kato M; Takada S; Kashida Y; Nomura M
    Toxicol Pathol; 1995; 23(3):385-92. PubMed ID: 7659960
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A comparative study of anxiogenic effects of fluoroquinolones in rats.
    Prabhu S; Rewari S
    Indian J Physiol Pharmacol; 1998 Jan; 42(1):135-8. PubMed ID: 9513807
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Antibacterial activity of norfloxacin, ofloxacin and ciprofloxacin according to resistance phenotypes to nalidixic acid and pefloxacin].
    Soussy CJ; Le Van Thoi J; Duval J
    Pathol Biol (Paris); 1990 May; 38(5):376-84. PubMed ID: 2367152
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Quantitative determination of ofloxacin, ciprofloxacin, norfloxacin and pefloxacin in serum by high pressure liquid chromatography.
    Groeneveld AJ; Brouwers JR
    Pharm Weekbl Sci; 1986 Feb; 8(1):79-84. PubMed ID: 2938073
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Adverse testicular effects of some quinolone members in rats.
    Abd-Allah AR; Aly HA; Moustafa AM; Abdel-Aziz AA; Hamada FM
    Pharmacol Res; 2000 Feb; 41(2):211-9. PubMed ID: 10623489
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparative articular toxicity of garenoxacin, a novel quinolone antimicrobial agent, in juvenile beagle dogs.
    Nagai A; Miyazaki M; Morita T; Furubo S; Kizawa K; Fukumoto H; Sanzen T; Hayakawa H; Kawamura Y
    J Toxicol Sci; 2002 Aug; 27(3):219-28. PubMed ID: 12238145
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparison of ciprofloxacin, ofloxacin and pefloxacin for the prevention of the bacterial infection in neutropenic patients with haematological malignancies.
    D'Antonio D; Piccolomini R; Iacone A; Fioritoni G; Parruti G; Betti S; Quaglietta AM; Accorsi P; Dell'Isola M; Favalli C
    J Antimicrob Chemother; 1994 Apr; 33(4):837-44. PubMed ID: 8056702
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [In vitro activity of new quinolones against Mycoplasma pathogenic to humans].
    Renaudin H; Quentin C; de Barbeyrac B; Bebear C
    Pathol Biol (Paris); 1988 May; 36(5):496-9. PubMed ID: 3136430
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Do tendon lesions occur during quinolone administration?].
    Shah P
    Dtsch Med Wochenschr; 2003 Oct; 128(42):2214. PubMed ID: 14562223
    [No Abstract]   [Full Text] [Related]  

  • 30. Partial Achilles tendon ruptures associated with fluoroquinolone antibiotics: a case report and literature review.
    McGarvey WC; Singh D; Trevino SG
    Foot Ankle Int; 1996 Aug; 17(8):496-8. PubMed ID: 8863030
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Biotransformation of selected gyrase inhibitors].
    Borner K; Lode H
    Infection; 1986; 14 Suppl 1():S54-9. PubMed ID: 3007367
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Diffusion of fluoroquinolones in the aqueous humor and crystalline lens].
    Lafaix C; Salvanet A; Fisch A; Forestier F; Montay G; Meulemans A
    Pathol Biol (Paris); 1987 Jun; 35(5 Pt 2):768-71. PubMed ID: 3309812
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparative effects of quinolones on human mononuclear leucocyte functions.
    Roche Y; Gougerot-Pocidalo MA; Fay M; Etienne D; Forest N; Pocidalo JJ
    J Antimicrob Chemother; 1987 Jun; 19(6):781-90. PubMed ID: 3497150
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Statin-induced calcific Achilles tendinopathy in rats: comparison of biomechanical and histopathological effects of simvastatin, atorvastatin and rosuvastatin.
    Kaleağasıoğlu F; Olcay E; Olgaç V
    Knee Surg Sports Traumatol Arthrosc; 2017 Jun; 25(6):1884-1891. PubMed ID: 26275370
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The comparative in-vitro activity of eight newer quinolones and nalidixic acid.
    King A; Phillips I
    J Antimicrob Chemother; 1986 Nov; 18 Suppl D():1-20. PubMed ID: 3468100
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [In vitro fluoroquinolone resistance in ocular bacterial isolates].
    Sun XG; Wang ZQ; Li R; Chen L; Jin XY; Luo SY
    Zhonghua Yan Ke Za Zhi; 2003 Mar; 39(3):163-6. PubMed ID: 12880574
    [TBL] [Abstract][Full Text] [Related]  

  • 37. In vitro activity of pefloxacin compared with five other quinolones on nalidixic acid-resistant proteae species.
    Piccolomini R; Cellini L; Allocati N; Di Girolamo A; Selan L; Scazzocchio F
    Chemioterapia; 1988 Oct; 7(5):287-91. PubMed ID: 3224396
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pefloxacin as a surrogate marker for quinolone susceptibility in
    Sharma P; Dahiya S; Kumari B; Balaji V; Sood S; Das BK; Kapil A
    Indian J Med Res; 2017 May; 145(5):687-692. PubMed ID: 28948961
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [In vitro activity of 4 fluoroquinolones against Klebsiella pneumoniae. Distribution according to phenotype resistance to aminoglycosides or beta-lactams].
    Miguères ML; Ronco E; Guenounou M
    Pathol Biol (Paris); 1990 May; 38(5):385-9. PubMed ID: 2195447
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Kinetics of 4-fluoroquinolones permeation into saliva.
    Kozjek F; Suturkova LJ; Antolic G; Grabnar I; Mrhar A
    Biopharm Drug Dispos; 1999 May; 20(4):183-91. PubMed ID: 10440793
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.